YTHDF2 and prostate carcinoma: The up‐regulation of YTHDF2 in prostate cancer was possibly contributed to the regulation of miR‐493‐3p, which increased the m6A level and inhibited tumour carcinogenesis by down‐regulating its downstream target YTHDF2 in prostate cancer.